Tag Archive for: alys

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology

ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata Significant progress made in advancing the Alys pipeline following $100m seed financing from Medicxi Boston, Massachusetts and Lausanne, Switzerland, 4th February 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) […]

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologies Vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need Boston, Massachusetts and Geneva, Switzerland, 12th February 2024 – Alys Pharmaceuticals, Inc. […]